Drug Discovery Featured Articles & Applications

1. Rethinking Disease Modification Through Targeted Immunotherapy 2/11/2026

   As understanding of immune-driven disease deepens, therapies that selectively correct dysregulated inflammation have the potential to reshape treatment paradigms.

2. New Approach Methods In Practice: Where Are We Today? 2/10/2026

   NAMs have moved beyond a technological promise, but now the current challenge is to operationalize their adoption.

3. Insights From The Non-Opioid Pain Therapeutics Summit: Human-Centric Translational Models And The Reawakening Of Pain Pipelines 2/2/2026

   The 2026 Inaugural Non-Opioid Pain Therapeutics Summit brought together a diverse group of scientists, clinicians, and drug hunters to discuss developing safe, effective pain medicines without the addictive properties associated with opioids.

4. AI For NAM-Ready Drug Development: Turning Promise Into Trust 1/30/2026

   AI is naturally situated for NAMs, and its value will be maximized when it is deployed as part of a rigorously validated, evidence-based strategy.

5. From Cyclization To The Clinic: The Rising Era Of Cyclic Peptide Therapeutics 1/28/2026

   The pharmaceutical industry is currently experiencing a golden era for cyclic peptide therapeutics.

6. Targeting Underlying Biology: Novel Combination Therapies For Chronic Disease 1/26/2026

   Combination therapies that incorporate cannabinoids and psychedelics signal an important shift in how complex chronic diseases are being approached. 

7. Schrödinger's Equation Turns 100: How Quantum Chemistry Is Improving Drug Discovery 1/23/2026

   On January 26th, 2026 as we celebrate this centennial milestone of Schrödinger’s Equation, it’s worth asking: What does quantum mechanics mean for drug discovery and biomolecular simulations?

8. Charting The Future Of Antimicrobial Resistance 1/21/2026

   We caught up with Ajit Parhi, Ph.D., CSO of TAXIS Pharmaceuticals, to discuss policy, precision science, and AI in battling antimicrobial resistance.

9. Annual Reflections And Predictions From The Editors' Roundtable 1/6/2026

   Understanding the full scope of the life science industry has never been more critical. Ray Dogum, Chief Editor of Drug Discovery Online, joins the Life Science Connect Editors’ Roundtable on a special episode of Better Biopharma podcast.

10. The FXI Gamble: To Bleed Less... Or To Protect Less? 1/2/2026

    A new generation of FXI and FXIa inhibitors is stepping in with bold promises to reduce bleeding while preserving direct oral anticoagulant-like efficacy. Is this the start of a new era?